
    
      The treatment period is composed of a 24-week double-blind period (week 1-24) and a 28-week
      open-label period (week 25-52). During the double-blind period, participants will receive 10
      mg or 25 mg dose of HSK7653, or linagliptin, and with matching placebo respectively. During
      the open-label period, all participants will receive 25 mg dose of HSK7653. All participants
      will receive a stable dose of metformin therapy in both the double-blind period and the
      open-label period.
    
  